Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / The inhibitory effect of Phα1β toxin on diabetic neuropathic pain involves the CXCR4 chemokine receptor.

< BACK TO ARCHIVE


Papers: 1 Feb 2020 - 7 Feb 2020


Animal Studies, Pharmacology/Drug Development


2020 Feb


Pharmacol Rep


http://www.ncbi.nlm.nih.gov/pubmed/32016848?dopt=Abstract


72


1

The inhibitory effect of Phα1β toxin on diabetic neuropathic pain involves the CXCR4 chemokine receptor.

Authors

The inhibitory effect of Phα1β toxin on diabetic neuropathic pain involves the CXCR4 chemokine receptor.
da Silva Junior C A, de Castro Junior C J, Pereira E M R, Binda N S, da Silva J F, do Nascimento Cordeiro M, Diniz D M, Cecilia F S, Ferreira J, Gomez M V
Pharmacol Rep. 2020 Feb; 72(1):47-54.
PMID: 32016848.

Abstract

Diabetic neuropathy is a common cause of painful diabetic neuropathy (PDN). C-X-C chemokine receptor type 4 (CXCR4) expression is increased in peripheral nerve samples from diabetes patients, suggesting a role for CXCR4 in PDN. Therefore, we evaluated the effects of Phα1β, ω-conotoxin MVIIA, and AMD3100 in a model of streptozotocin (STZ)-induced PDN in rodents and naïve model of rats with the activation of the CXCR4/stromal cell-derived factor 1 (SDF-1) signal.
Read This Paper